Treatment of corneal neovascularization using riboflavin photo-activation
Official title: Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and/or Infection
Run by Price Vision Group · NCT04787471 · Data updated 2026-11-12
This study is testing if a light treatment with riboflavin can help people with corneal neovascularization feel better and improve their eye health.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 138 (estimated) |
| Sponsor | Price Vision Group Industry-sponsored |
| Locations | 1 site (Indianapolis, Indiana) |
| Status | Recruiting |
| Started | May 3, 2021 |
| Main results expected | July 15, 2029 |
| Study ends | September 15, 2029 |
| Registry record updated | September 17, 2026 |
| Trial ID | NCT04787471 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with active corneal neovascularization due to inflammation or infection.
✕Probably not a fit
Patients with known sensitivities to the treatment medications or those who are pregnant or lactating may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the safety and effectiveness of riboflavin photo-activation for treating corneal neovascularization, which may occur with or without inflammation or infection. Participants will undergo a 30-minute or 10-minute photoactivation procedure using a 0.1% riboflavin solution. The study will assess how well this treatment can reduce vascularization and improve corneal health. It is designed for patients experiencing significant corneal issues related to neovascularization.
Why it matters
Potential benefit: If successful, this treatment could significantly improve vision and reduce the risk of corneal transplant rejection for patients with corneal neovascularization.
How similar studies have gone: Other studies have shown promise in using riboflavin photo-activation for corneal conditions, suggesting a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years of age or older * With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids. * Signed written informed consent. Exclusion Criteria: * Known sensitivity to treatment medications * Current condition that in the investigator's opinion could compromise safety or data integrity. * Pregnancy (including plan to become pregnant) or lactation during the course of the study
Where it's running
-
Price Vision Group
Indianapolis, Indiana, United States Recruiting
Study contacts
- Principal investigator: Francis W Price, Jr., MD — Price Vision Group
- Study coordinator: Marianne Price, PhD
- Email: mprice@cornea.org
- Phone: 317-814-2990
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Intrastromal anti-VEGF injection for corneal neovascularization
We will test whether injecting anti-VEGF medicine into the cornea helps adults with corneal neovascularization caused by herpes simplex keratitis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.